Twist Bioscience (TWST)
(Delayed Data from NSDQ)
$43.66 USD
+1.20 (2.83%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $43.63 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.66 USD
+1.20 (2.83%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $43.63 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Zacks News
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of -8.86% and 5.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best ETFs of Last Week
by Sanghamitra Saha
Wall Street offered a mixed performance last week.
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Take the Zacks Approach to Beat the Markets: NVIDIA, Twist Bioscience, Ollie's Bargain Outlet in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
by Zacks Equity Research
Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
by Zacks Equity Research
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Twist Bioscience (TWST) have performed compared to their sector so far this year.
What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Twist Bioscience (TWST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 5.95% and 6.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Soars 12.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
5 Best Performing Stocks of the Top ETF of November
by Sweta Killa
ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 13.83% and 5.52%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 7.95% and 14.09%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery
by Zacks Equity Research
Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 11.40% and 5%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -29.06% and 7.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Twist Bioscience (TWST) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Twist Bioscience (TWST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Twist Bioscience (TWST) Upgraded to Buy: Here's Why
by Zacks Equity Research
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 26.05% Upside in Twist Bioscience (TWST): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Twist Bioscience (TWST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.